Wedbush raised its price target for Viridian Therapeutics to $44 from $42 after recent updates.

Nov 9, 2026, 6:10 PM ETOpinionRead the original at moomoo.com

Good for VRDN

Wedbush raised its target after clinical updates and kept its Outperform rating, supporting a positive view. The story gives no details about those updates, so the support rests on the firm's opinion.

VRDN · Viridian Therapeutics, Inc.

AI read · Good for VRDN

The AI's read

The firm's view improved after clinical updates, which points to confidence in Viridian's progress. But the story reports no trial findings or other details, so this is an analyst opinion, not new proof of progress.

Get alerts for VRDN

Follow Viridian Therapeutics, Inc. (VRDN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VRDN

Free on the App Store and Google Play, or on the web.